Evidence map›Paper›PMID 35718073›Full record

ReviewPractical radiation oncology

Patterns of Recurrence After Primary Local Therapy for Pancreatic Ductal Adenocarcinoma - A Critical Review of Rationale and Target Delineation for (Neo)Adjuvant Radiation Therapy.

Krishan R Jethwa, Shane S Neibart, Mark J Truty, Salma K Jabbour, Christopher L Hallemeier

Open access · greenAbstract readReview
In one paragraph

Review in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer.Clinical and experimental gastroenterology · 2024
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Krishan R JethwaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: jethwa.krishan@mayo.edu.
Shane S NeibartDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.
Mark J TrutyDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.
Salma K JabbourDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.
Christopher L HallemeierDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USRutgers, The State University of New Jersey · US

Funding

Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)R50CA275877 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Salma Jabbour · 2023 to 2026
$785k
NCI NIH HHS R50 CA275877
6 · The paper itself

Abstract

purposeThe purpose of this work was to describe pancreatic ductal adenocarcinoma (PDAC) patterns of locoregional spread and recurrence to help guide clinicians on (neo)adjuvant radiation therapy (RT) planning strategies and target volume delineation. METHODS AND MATERIALS: A comprehensive review of clinical data was performed to describe PDAC patterns of locoregional spread, including extrapancreatic tumor extension, perineural invasion, regional lymph node involvement, and patterns of disease recurrence as influenced by (neo)adjuvant treatment strategy.

resultsThis review describes PDAC patterns of spread, disease progression, and evolving treatment techniques. Based upon this data, we advocate for inclusion of elective at-risk regions of extrapancreatic extension, perineural invasion, and lymphatic spread for patients receiving neoadjuvant RT.

conclusionsThis review provides a nuanced description of PDAC patterns of spread and recurrence to guide clinicians on target volume delineation and planning strategies to maximize the effectiveness of neo(adjuvant) RT delivery for patients with PDAC. Further prospective studies are needed to better define the optimal RT dose, fractionation regimens, and target volumes to be used in the (neo)adjuvant setting.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalRadiotherapy, Adjuvant

Identifiers

PMID35718073
PMCPMC10905628
OpenAlexW4283018894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.